Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry.

A rapid, sensitive and selective liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of piroxicam, meloxicam and tenoxicam in human plasma was developed. Piroxicam, meloxicam, tenoxicam and isoxicam (internal standard) were extracted from human plasma with ethyl acetate at acidic pH and analyzed on a Sunfire column with the mobile phase of methanol:ammonium formate (15 mM, pH 3.0) (60:40, v/v). The analytes were detected using a mass spectrometer, equipped with electrospray ion source. The instrument was set in the multiple-reaction-monitoring (MRM) mode. The standard curve was linear (r=1.000) over the concentration range of 0.50-200 ng/ml. The coefficient of variation (CV) and relative error (RE) for intra- and inter-assay statistics at three QC levels were 1.0-5.4% and -5.9 to 2.8%, respectively. The recoveries of piroxicam, meloxicam and tenoxicam ranged from 78.3 to 87.1%, with that of isoxicam being 59.7%. The lower limit of quantification for piroxicam, meloxicam and tenoxicam was 0.50 ng/ml using a 100 microl plasma sample. This method was successfully applied to a pharmacokinetic study of piroxicam after application of transdermal piroxicam patches to humans.

[1]  H. D. De brabander,et al.  Multi-residue liquid chromatography/tandem mass spectrometry method for the detection of non-steroidal anti-inflammatory drugs in bovine muscle: optimisation of ion trap parameters. , 2004, Rapid communications in mass spectrometry : RCM.

[2]  Hoo-Kyun Choi,et al.  Effect of ethanolamine salts and enhancers on the percutaneous absorption of piroxicam from a pressure sensitive adhesive matrix , 2003 .

[3]  C. Suann,et al.  The detection of piroxicam, tenoxicam and their metabolites in equine urine by electrospray ionisation ion trap mass spectrometry. , 2004, Rapid Communications in Mass Spectrometry.

[4]  Shivaprakash,et al.  LC determination and pharmacokinetics of meloxicam. , 2002, Journal of pharmaceutical and biomedical analysis.

[5]  S. Santoyo,et al.  Study of the Complexation Behavior of Tenoxicam with Cyclodextrins in Solution: Improved Solubility and Percutaneous Permeability , 2002, Drug development and industrial pharmacy.

[6]  C. Huck,et al.  Sample pretreatment and determination of non steroidal anti-inflammatory drugs (NSAIDs) in pharmaceutical formulations and biological samples (blood, plasma, erythrocytes) by HPLC-UV-MS and micro-HPLC. , 2005, Current medicinal chemistry.

[7]  A. D. de Jager,et al.  Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of meloxicam in human plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  B. Lippold,et al.  Prediction of the Efficacy of Cutaneously Applied Nonsteroidal Anti-inflammatory Drugs from a Lipophilic Vehicle , 2000, Arzneimittelforschung.

[9]  S. Dadashzadeh,et al.  LC determination of piroxicam in human plasma. , 2002, Journal of pharmaceutical and biomedical analysis.

[10]  W. Baeyens,et al.  Application of an alkyl-diol silica precolumn in a column-switching system for the determination of meloxicam in plasma. , 2003, Journal of pharmaceutical and biomedical analysis.

[11]  S. Santoyo,et al.  Sensitive LC determination of piroxicam after in vitro transdermal permeation studies. , 2001, Journal of pharmaceutical and biomedical analysis.

[12]  I. Oh,et al.  Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats. , 2000, International journal of pharmaceutics.

[13]  S. Santoyo,et al.  Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  H. Gwak,et al.  Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. , 2002, International journal of pharmaceutics.

[15]  J. Fernández,et al.  Piroxicam quantitation in human plasma by high-performance liquid chromatography with on- and off-line solid-phase extraction. , 1999, Journal of Chromatography A.

[16]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.